Developer of an AI-driven drug-discovery technology designed to focus on developing and screening novel compounds for psychedelic medicine. The company uses machine learning to find novel psychedelic drug compounds aiming to minimize adverse effects and maximize the clinical benefits of the drugs, enabling scientists to unlock the kaleidoscope of untapped possibilities in psychedelic medicine.

The foundations of our scientific hypothesis originate from our research project that started four years ago at the University of Chemistry and Technology in Prague (UCT) and later included computational work done at University College London (UCL).

Inspired by seminal research into neuroplasticity and mechanisms of psychedelic action published at that time, this project had discovered that a largely unexplored class of psychedelic compounds may provide significant therapeutic benefits over classical psychedelics, according to both preclinical and clinical evidence. The bulk of the project then combined computational drug design with organic synthesis to eventually yield two distinct series of promising drug candidates.